John Wu Ph.D. | Rocky Shih Ph.D. | |
•M.S. The Ohio State University
•PTS International, Inc. founder •PTS R&D/clinical investigator |
•Co-Founder
•PhD.University of Texas •Prof. University of Texas(San Antonio)
|
♦ Management Team ♦
Lester John Wu Chairman |
Mao Yuan Lin General Manager |
|
•PTS International Inc. Chairman
•PTS ASIA Limited. Chairman
•Beijing Vision Drugs Development Limited Chairman
|
•Gongwin Biopharm Co.Ltd General Manager
•More than 20 years of financial operations experience in Taiwan, China, Asia Pacific
•More than 20 years of experience in biotechnology pharmaceutical industry |
♦ R&D Team ♦
R&D Division Charles Yang Ph.D. |
Preclinical Research Division Shun-Chi Wu Ph.D. |
|
• Ph.D. National Tsing Hua Univ.
|
• Ph.D., Institute of Biochemistry and Molecular Biology, College of Medicine National Taiwan University |
|
Medical Affairs Division Eric Tu Ph.D. |
||
• Ph.D. UCSD • > 10 yrs cancer R&D experience • Project management |
||
|
||
♦ Management Team ♦
Business Development Manager |
Administration Division |
|
Droctor of Medicine
|
•M.S. National Taipei Univ.
•15 years of accounting experience, familiar with internal control establishment •Good at joint venture and contract related matters |
♦ Cooperative consultant ♦
Michael G. Simoff MD | Nanshan Zhong MD | |
•Henry Ford Medical Center, Detroit, USA •Specialties:Pulmonary Disease, Critical Care Medicine •Services:Cancer Research, Lung and Thoracic Cancer |
•Director of the Guangzhou Institute of Respiratory Diseases
•Member of WHO Advisory Panel on Smoking & Health •Foremer President of the Chinese Medical Association
|
|
Zhe Ren Zhuang Ph.D. | You Xiang Wang Ph.D. | |
•Ph.D. MIT
|
•Taipei Medical University Ph.D. |
|
Yi Hong Chen Ph.D. | Peng Fei Luo Dr. | |
•Ph.D. National Taiwan University •Prof. China Medical University •Specialties:Neurophysiology、Pharmacology |
•GUANGDONG PHARMACEUTICAL UNIVERSITY Hospital •Specializes in tumor interventional therapy, especially in the treatment of liver cancer, intestinal cancer and liver metastasis. |
|
Pierre Xiao | Ju Hsiang Ho | |
•M.S. National Taiwan Univ. •20 years of experience in new drug development planning •Specialized in global marketing strategy, new drug development planning |
•M.S. Asian Institute of Management •Experienced in Deloitte Taiwan •35 years of accounting experience |
|